12 Hrs_1777292798912_197359786.jpg&w=48&q=75)
Source:
عكس السير
Britain adopts innovative "living drug" for cancer
Britain has launched an innovative treatment for leukemia that relies on reprogramming the patient's immune cells to attack the cancer cells. It is known as obe-cel, a second-generation CAR-T therapy. The treatment has shown promising results, with 77% of patients entering a remission phase, and nearly half of them being cancer-free after about three and a half years of treatment, with lower rates of serious complications compared to previous versions. This therapy is considered the first application of its kind in England through the National Health Service (NHS), and it is expected to benefit around 50 patients annually. It represents an important step forward in the field of immunotherapy for this specific type of blood cancer.
Size: 120%Text Size
Notice: This Is an AI-Generated Summary
Comments (0)